Leadership

 

Krisztina Zsebo, Ph.D., VasoRx CEO, Director, and Co-founder Dr. Zsebo is a biopharmaceutical veteran with 35 years of experience in the Biotechnology industry and has been involved in numerous successful ventures.   She was CEO & President of Celladon Corporation, for 11 years and took the company public. She was also an Entrepreneur in Residence at Enterprise Partners Venture Capital. Prior to joining Enterprise, she was CEO & President of Remedyne Corporation. Before coming to Remedyne she was Executive Vice President of Connetics Corporation.  Dr. Zsebo also headed the Biopharmaceutical and Implant Division of ALZA Corporation, where she was responsible for the division which developed and filed the NDA for Viadur®, an implantable drug/device for prostate cancer patients. At Cell Genesys, where she was Executive Vice President of Research and Product Development, she managed the Xenotech division where Xenomouse was developed. It was spun off to become Abgenix, one of the most successful biotech companies.  Earlier in her career, Kris spent eight years at Amgen in research and product development where she worked on the discovery of NEUPOGEN®, as well as Stem Cell Factor, and various aspects of EPOGEN® development. Dr. Zsebo received a B.S. in Biochemistry from the University of Maryland, a M.S. in Biochemistry and Biophysics from Oregon State University and a PhD in Comparative Biochemistry and Molecular Biology from the University of California, Berkeley.

 

Rebecque laba, VP Finance & Administration  Ms. Laba has served as our Vice President Finance and Administration since November 2020. She has over 25 years of experience in biotechnology serving in executive roles with direct oversight of finance and accounting, business operations, and corporate governance, among others. Ms. Laba was Vice President Finance and Corporate Operations at Celladon Corporation where she led the company through an IPO. Prior to Celladon she held senior roles at Idun Pharmaceuticals having a lead role in its acquisition by Pfizer. Ms. Laba has raised over $350MM in private and public equity, and debt financings and has participated in multiple M&A transactions.